Description of the studies included in the review*
| Paper | Publication year | Cost country | Age range (mean) | Modelling† | Prevention category‡ | Treatment duration | Discount factor (%) | Funding source |
|---|---|---|---|---|---|---|---|---|
| *In total 24 studies were included in the final analysis. †Primary: based on observations from a randomised trial. Secondary: based on expectations from a theoretical model. ‡Secondary prevention is among patients with clinical coronary heart disease or cardiovascular disease, primary prevention among apparently healthy persons. | ||||||||
| Ashraf17 | 1996 | United States | 60 | Both | Secondary | 3,10 years | 5 | Pharmaceutical Company |
| Caro18 | 1997 | United Kingdom | 45–64 (55) | Primary | Primary | 5 years | 6 | Pharmaceutical Company |
| Ganz19 | 2000 | United States | 75–84 | Secondary | Secondary | Lifetime | 3 | University |
| Goldman21 | 1991 | United States | 35–84 | Secondary | Both | Lifetime | 5 | Government |
| Goldman20 | 1993 | United States | 35–44 | Secondary | Primary | Lifetime | 5 | Government |
| Grover22 | 1999 | Canada | 40–70 | Secondary | Secondary | Lifetime | 3 | University |
| Grover24 | 2000 | Canada | 40–70 | Secondary | Both | Lifetime | 5 | Pharmaceutical Company |
| Grover23 | 2001 | Canada | 40–70 | Secondary | Both | Lifetime | 3 | Pharmaceutical Company |
| Hamilton25 | 1995 | Canada | 30–70 | Secondary | Primary | Lifetime | 5 | Pharmaceutical Company |
| Hay26 | 1991 | United States | 35–55 | Secondary | Primary | Lifetime | 5 | Pharmaceutical Company |
| Huse27 | 1998 | United States | 45–65 | Secondary | Both | Lifetime | 3 | Pharmaceutical Company |
| Johannesson28 | 1997 | Sweden | 35–70 | Secondary | Secondary | 5 years | 5 | Pharmaceutical Company |
| Jonsson39 | 1996 | Sweden | 35–70 (59) | Primary | Secondary | 5 years | 5 | Pharmaceutical Company |
| Jonsson40 | 1999 | Sweden | 35–70 (60) | Primary | Secondary | 5 years | 3 | University |
| Martens29 | 1994 | Canada | 45 | Secondary | Primary | Lifetime | 5 | Pharmaceutical Company |
| Muls30 | 1998 | Belgium | 60 | Both | Secondary | 3,10 years | 5 | Pharmaceutical Company |
| Perreault31 | 1998 | Canada | 44–56–57 | Secondary | Primary | Lifetime | 5 | University |
| Pharoah32 | 1996 | United Kingdom | 45–64 | Secondary | Both | 10 years | 5 | None |
| Pickin33 | 1999 | United Kingdom | 55,58 | Secondary | Both | 5years, lifetime | 6 | University |
| Russell34 | 2001 | Canada | 45–65 | Secondary | Both | Lifetime | 5 | Pharmaceutical Company |
| Szucs36 | 1998 | Germany | 45–65 (59) | Primary | Secondary | 5 years | 0 | University |
| Szucs35 | 2000 | Germany | 45–65 (60) | Primary | Secondary | 5 years | 3 | University |
| Riviere38 | 1997 | Canada | 35–70 (59) | Secondary | Secondary | 5, 10, lifetime | 5 | Pharmaceutical Company |
| Van Hout37 | 2001 | Netherlands | 25–75 | Secondary | Both | 5years, lifetime | 5 | University |